Key takeaways from the updated multidisciplinary European MASLD guidelines

Area of Science:

• Hepatology and Gastroenterology
• Endocrinology and Metabolism
• Clinical Practice Guidelines

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern.
• Existing management strategies require updated, evidence-based clinical practice guidelines.
• The European Association for the Study of the Liver, Diabetes, and Obesity have collaborated to address this need.

Purpose of the Study:

• To present new European clinical practice guidelines for MASLD management.
• To provide detailed recommendations on diagnosis, risk stratification, monitoring, treatment, and prevention.
• To incorporate recent advancements in pharmacological and non-invasive diagnostic approaches.

Main Methods:

• Development of guidelines by three major European scientific societies.
• Review and synthesis of current evidence on MASLD diagnosis and management.
• Inclusion of recommendations for lifestyle interventions, cardiometabolic risk factor management, and novel pharmacotherapies.

Main Results:

• Guidelines emphasize lifestyle interventions (weight reduction, diet, exercise, alcohol abstinence) as foundational.
• Incretin mimetics (semaglutide, tirzepatide) show promise for ameliorating metabolic dysfunction-associated steatohepatitis (MASH).
• Novel recommendations include non-invasive tests (NITs) for screening and fibrosis detection, and potential use of resmetirom for MASH fibrosis (≥F2).

Conclusions:

• The new guidelines provide a comprehensive framework for MASLD management.
• A multi-faceted approach combining lifestyle, risk factor control, and targeted therapies is recommended.
• The guidelines highlight the evolving landscape of MASLD treatment, including new pharmacological options and non-invasive monitoring tools.